Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilofotase alfa for prevention of renal damage after cardiac surgery
2023-505859-45-00Phase 2Completed
- Sponsor
- AM-Pharma
- Start
- Dec 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) and chronic kidney disease (CKD) comparing Ilofotase alfa with Placebo (2 arms). Primary endpoint: Serum creatinine ratio post-surgery vs pre-surgery baseline. Started Dec 2023; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-505859-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505859-45-00.